{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:30:39Z","timestamp":1790544639068,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T00:00:00Z","timestamp":1513814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union Seventh Framework Program under the ASKLEPIOS","award":["602825"],"award-info":[{"award-number":["602825"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2017.12.051","type":"journal-article","created":{"date-parts":[[2017,12,24]],"date-time":"2017-12-24T03:39:50Z","timestamp":1514086790000},"page":"4660-4662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["The path towards effective antivirals against rabies"],"prefix":"10.1016","volume":"37","author":[{"given":"Dirk","family":"Jochmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.12.051_b0005","unstructured":"WHO Expert Consultation on Rabies. Second report. World Health Organization technical report series. 2013\/09\/28 ed2013. p. 1\u2013139."},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2017.12.051_b0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jns.2014.02.013","article-title":"Survival from rabies encephalitis","volume":"339","author":"de Souza","year":"2014","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2017.12.051_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP2851","article-title":"Antiviral therapy for human rabies","volume":"20","author":"Appolinario","year":"2015","journal-title":"Antivir Ther"},{"issue":"6","key":"10.1016\/j.vaccine.2017.12.051_b0020","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/INF.0000000000000641","article-title":"The, \u201cMilwaukee protocol\u201d for treatment of human rabies is no longer valid","volume":"34","author":"Wilde","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2017.12.051_b0025","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res"},{"issue":"7","key":"10.1016\/j.vaccine.2017.12.051_b0030","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2017.12.051_b0035","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/infdis\/jiv586","article-title":"Efficacy of Favipiravir (T-705) in rabies postexposure prophylaxis","volume":"213","author":"Yamada","year":"2016","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2017.12.051_b0040","doi-asserted-by":"crossref","first-page":"e1004995","DOI":"10.1371\/journal.ppat.1004995","article-title":"Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2\u2032-Fluoro-4\u2032-chloromethyl-cytidine triphosphate","volume":"11","author":"Deval","year":"2015","journal-title":"PLoS Pathog"},{"issue":"12","key":"10.1016\/j.vaccine.2017.12.051_b0045","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1016\/j.bmcl.2015.04.073","article-title":"Discovery of beta-D-2\u2032-deoxy-2\u2032-alpha-fluoro-4\u2032-alpha-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases","volume":"25","author":"Clarke","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"issue":"7496","key":"10.1016\/j.vaccine.2017.12.051_b0050","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.12.051_b0055","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-Nucleoside (GS-5734) for the treatment of ebola and emerging viruses","author":"Siegel","year":"2017","journal-title":"J Med Chem"},{"issue":"20","key":"10.1016\/j.vaccine.2017.12.051_b0060","doi-asserted-by":"crossref","first-page":"10808","DOI":"10.1128\/JVI.00977-09","article-title":"Peptides that mimic the amino-terminal end of the rabies virus phosphoprotein have antiviral activity","volume":"83","author":"Castel","year":"2009","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17318121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17318121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T21:43:58Z","timestamp":1564177438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17318121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":12,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X17318121"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.12.051","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The path towards effective antivirals against rabies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.12.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}